Hand transplants get a boost: new drug may reduce rejection risk
NCT ID NCT02310867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests whether a hand transplant from a deceased donor, combined with the immunosuppressant belatacept (Nulojix), can help people with below-elbow limb loss use their new hand in daily tasks. Fifty participants aged 18-65 will be followed for 18 months. The main goal is improved hand function, but risks include rejection, infection, and side effects from long-term anti-rejection drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belatacept (Nulojix) plus hand transplant surgery
What this could lead to
If successful, this could offer a way for people with below-elbow limb loss to regain hand function for daily activities, using a new immunosuppressant to help prevent rejection.
What could go wrong
This is an early phase 2 study with only 50 participants, so results may not apply to everyone. Risks include organ rejection, serious infection, and side effects from long-term immunosuppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States